AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KYMR

Mainolfi Nello sold $9.2M of KYMR

Mainolfi Nello (Chief Executive Officer) sold 80,000 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $115.29 ($112.80–$116.56, $9.22M total) across 5 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mainolfi Nello
Published Jul 2, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 10:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KYMR
Neutral
medium confidence
Mentioned
$KYMR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRNeutralLow
01

Why it matters

The CEO’s open-market sale totaling ~$9.22M could slightly pressure sentiment, but the stated 10b5-1 plan suggests the trades were scheduled in advance.

02

Market read

This provides a fresh, primary-source datapoint on insider behavior, but it does not include operational or financial updates that would materially reset valuation expectations.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or financing news, the signal is mostly sentiment-level.

Relevance 5/10Novelty 5/10Timing: Filed July 2 after trades on July 1

Background

The article is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc. (KYMR).

Company-level read

Ticker impact

$KYMRNeutralMedium confidence
Context

Kymera Therapeutics CEO Mainolfi Nello sold 80,000 shares in open-market trades totaling about $9.22M under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be modest unless paired with other company-specific catalysts.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size ($9.22M) and role (CEO), but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens signal strength.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on Kymera’s prospects.

Key entities

  • issuer
    Kymera Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CEO sold 80,000 shares totaling ~$9.22M.

  • insider
    Mainolfi Nello

    CEO and director who executed the open-market sales under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KYMR insider trading history →

Related articles

$KYMRMed

Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera (KYMR) reported Q3 2026 earnings, highlighting progress in its pipeline, including Phase IIb data for KT-621 in atopic dermatitis (AD) expected by year-end. The BROADEN 2 study's placebo-controlled portion is complete, with 98% of eligible patients enrolling in the open-label extension. The company also discussed market research indicating a demand for safe, effective oral treatments for AD.

finance.yahoo.com
$KYMRMed

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics reported Q3 results, highlighting 98% inhibition of TLR7/8-stimulated interferon-beta levels and positive phase I data for KT-579. The company plans a phase Ib lupus study (LUMORA) in early 2027. KT-621 is expected to show atopic dermatitis efficacy comparable to dupilumab. Q3 R&D expenses were $128.5M, with cash position of $1.6B providing runway into 2029.

finance.yahoo.com
$KYMRMedAI 8/10

Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement

Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.

investing.com
$KYMRHigh

Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary

Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.

tradingview.com
$KYMRHighAI 8/10

Kymera reports phase 1 data for KT-579, plans lupus trial

Kymera Therapeutics (KYMR) reported phase 1 trial results for KT-579, showing significant IRF5 degradation and biomarker reductions. The company plans a phase 1b lupus trial in 2027. Q3 2026 net loss was $132.0M, up from $82.2M in 2025, with R&D expenses increasing. Cash reserves are $1.6B, expected to last into 2029. Updates on other clinical trials were also provided.

investing.com